Highlights from ASCO Annual Meeting 2024, Leukemia Edition

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting with a focus on leukemia, as well as Healio’s top headlines from the meeting.

Jorge E. Cortes, MD, discusses how asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia. :27

Oreofe O. Odejide, MD, MPH, highlights the importance of this study. 3:30

Read the full coverage here:

https://www.healio.com/news/hematology-oncology/20240531/asciminib-may-transform-treatment-paradigm-for-chronic-myeloid-leukemia

New approach ‘redefining what is a suitable donor’ for stem cell transplant

Source: Al Malki MM, et al. Abstract 6503. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago.

Disclosures:

Cortes reports research funding to his institution from or consultant/advisory roles with Gilead Sciences, Jazz Pharmaceuticals, Novartis, Pfizer, Takeda and other companies.